Annual Cash & Cash Equivalents
$4.59 M
-$15.46 M-77.09%
December 31, 2023
Summary
- As of February 8, 2025, NRXP annual cash & cash equivalents is $4.59 million, with the most recent change of -$15.46 million (-77.09%) on December 31, 2023.
- During the last 3 years, NRXP annual cash & cash equivalents has risen by +$2.74 million (+147.18%).
- NRXP annual cash & cash equivalents is now -83.35% below its all-time high of $27.61 million, reached on December 31, 2021.
Performance
NRXP Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$1.65 M
-$252.00 K-13.28%
September 30, 2024
Summary
- As of February 8, 2025, NRXP quarterly cash and cash equivalents is $1.65 million, with the most recent change of -$252.00 thousand (-13.28%) on September 30, 2024.
- Over the past year, NRXP quarterly cash and cash equivalents has increased by +$327.00 thousand (+24.79%).
- NRXP quarterly cash and cash equivalents is now -95.91% below its all-time high of $40.20 million, reached on March 31, 2022.
Performance
NRXP Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
NRXP Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -77.1% | +24.8% |
| 3 y3 years | +147.2% | -91.0% |
| 5 y5 years | +147.2% | - |
NRXP Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -83.3% | at low | -95.9% | +24.8% |
| 5 y | 5-year | -83.3% | +147.2% | -95.9% | +24.8% |
| alltime | all time | -83.3% | +147.2% | -95.9% | +24.8% |
NRx Pharmaceuticals Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $1.65 M(-13.3%) |
| Jun 2024 | - | $1.90 M(+43.9%) |
| Mar 2024 | - | $1.32 M(-71.3%) |
| Dec 2023 | $4.59 M(-77.1%) | $4.59 M(-48.4%) |
| Sep 2023 | - | $8.90 M(-40.5%) |
| Jun 2023 | - | $14.97 M(-9.3%) |
| Mar 2023 | - | $16.51 M(-17.7%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2022 | $20.05 M(-27.4%) | $20.05 M(+9.9%) |
| Sep 2022 | - | $18.25 M(-25.7%) |
| Jun 2022 | - | $24.55 M(-38.9%) |
| Mar 2022 | - | $40.20 M(+45.6%) |
| Dec 2021 | $27.61 M(+1384.9%) | $27.61 M(-29.0%) |
| Sep 2021 | - | $38.88 M(+190.5%) |
| Jun 2021 | - | $13.39 M(+620.1%) |
| Dec 2020 | $1.86 M | $1.86 M |
FAQ
- What is NRx Pharmaceuticals annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for NRx Pharmaceuticals?
- What is NRx Pharmaceuticals annual cash & cash equivalents year-on-year change?
- What is NRx Pharmaceuticals quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for NRx Pharmaceuticals?
- What is NRx Pharmaceuticals quarterly cash and cash equivalents year-on-year change?
What is NRx Pharmaceuticals annual cash & cash equivalents?
The current annual cash & cash equivalents of NRXP is $4.59 M
What is the all time high annual cash & cash equivalents for NRx Pharmaceuticals?
NRx Pharmaceuticals all-time high annual cash & cash equivalents is $27.61 M
What is NRx Pharmaceuticals annual cash & cash equivalents year-on-year change?
Over the past year, NRXP annual cash & cash equivalents has changed by -$15.46 M (-77.09%)
What is NRx Pharmaceuticals quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of NRXP is $1.65 M
What is the all time high quarterly cash and cash equivalents for NRx Pharmaceuticals?
NRx Pharmaceuticals all-time high quarterly cash and cash equivalents is $40.20 M
What is NRx Pharmaceuticals quarterly cash and cash equivalents year-on-year change?
Over the past year, NRXP quarterly cash and cash equivalents has changed by +$327.00 K (+24.79%)